Sophia Antipolis, France, Nov. 22, 2007 - ...Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United-States during the first quarter of 2009... [PDF] NicOx’ Press Release - PDF en Français -
Thursday, November 22, 2007
NicOx’ naproxcinod phase 3 results
Sophia Antipolis, France, Nov. 22, 2007 - ...Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United-States during the first quarter of 2009... [PDF] NicOx’ Press Release - PDF en Français -
